Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Outcomes after biochemical or clinical progression in patients with multiple myeloma
Goldman‐Mazur, Sarah , Kapoor, Prashant , Lacy, Martha Q. , Gertz, Morie A. , Buadi, Francis K. , Hayman, Suzanne R. , Dingli, David , Kourelis, Taxiarchis , Warsame, Rahma , Binder, Moritz , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Visram, Alissa , Dispenzieri, Angela , Lacy, Martha Q , Gertz, Morie A , Buadi, Francis K , Kourelis, Taxiarchis , Warsame, Rahma , Muchtar, E , Leung, Nelson , Binder, Moritz , Fonder, Amie , Hwa, Yi Lisa, Kumar, Shaji K , Dingli, David , Dispenzieri, Angela , Gonsalves, Wilson I. , Muchtar, Eli , Leung, Nelson , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | April 12, 2022 | Volume: 7 | Issue: 6 | Pages: 909-917

10.1182/bloodadvances.2022007082 | PMID 35413102 Get It

Abstract Almost all patients with multiple myeloma (MM) eventually relapse, either asymptomatically or with end-organ damage. However, it remains unclear whether initiating therapy at the time of biochemical progression (BP) improves the outcomes compared with initiating therapy at the clinical progression (CP) stage. Here, we retrospectively assessed 1347 patients with relapsed MM. Most progressions were BP (60.4%); 39.6% had CP. The most prevalent symptoms at relapse were new or evolving bone disease (80.9%), anemia (38.0%), and renal failure (12.7%). Patients with BP had longer median time from second-line treatment to the next treatment compared with patients who had CP (17.0 vs 9.6 months; P < .001) as well as longer median overall survival from first relapse (59.4 vs 26.2 months; P < .001). Male sex (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.02-2.18; P = .04), plasma cell labeling index ≥2% (OR, 1.58; 95% CI, 1.02-2.45; P = .04), and extramedullary disease at diagnosis (OR, 1.84; 95% CI, 1.08-3.13; P = .03) were associated with higher risk of CP, whereas very good partial remission or better had decreased risk of CP (OR, 0.62; 95% CI, 0.43-0.91; P = .02). To conclude, patients with CP have inferior postprogression outcomes compared with patients who have BP. Patients with deeper response to first-line therapy are less likely to develop CP. The presence of a specific CRAB (C, hypercalcemia; R, renal failure; A, anemia; B, bone disease) symptom at diagnosis predicts for the development of similar CRAB symptoms at relapse.
Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
Adashek, Jacob J. , Menta, Arjun K. , Reddy, Neha K. , Desai, Aakash , Roszik, Jason , Subbiah, Vivek , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Molecular Cancer Therapeutics | April 12, 2022 | Volume: 21 | Issue: 6 | Pages: 871-878

10.1158/1535-7163.mct-21-0950 | PMID 35413124 Get It

Abstract BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600–mutated colorectal cancer has prevented its tissue-agnostic drug development. We reviewed the AACR GENIE database for the prevalence of BRAF V600 mutations across tumor types. We reviewed the literature for case reports of clinical responses, outcomes in patients with BRAF V600 mutation—positive nonmelanoma malignancies who received BRAF inhibitor therapy, and data from published adult and pediatric trials. BRAF V600 mutations are prevalent across multiple nonmelanoma malignancies (>40 different tumor types), lead to oncogene addiction, and are clinically actionable in a broad range of adult and pediatric nonmelanoma rare malignancies. Continued tissue-agnostic drug development is warranted beyond the current BRAF plus MEK approved cancers.
Rasch‐calibrated Intermittent Exotropia Symptom Questionnaire for Children
Holmes, Jonathan M., Leske, David A., Hercinovic, Amra, Hatt, Sarah R., Chandler, Danielle L., Li, Zhuokai, Melia, B. Michele, Chen, Angela M., Erzurum, Sergul Ayse, Crouch, Eric R., Jenewein, Erin C., Kraker, Raymond T., Cotter, Susan A., Group, Pediatric Eye Disease Investigator, Holmes, Jonathan M. , Holmes, Jonathan M., Leske, David A., Hercinovic, Amra, Hatt, Sarah R., Chandler, Danielle L., Li, Zhuokai, Melia, B. Michele, Chen, Angela M., Erzurum, Sergul Ayse, Crouch, Eric R., Jenewein, Erin C., Kraker, Raymond T., Cotter, Susan A., Group, Pediatric Eye Disease Investigator, Holmes, Jonathan M.

Mayo Clinic

Optometry and Vision Science | April 12, 2022 | Volume: 99 | Issue: 6 | Pages: 513-520

10.1097/opx.0000000000001901 | PMID 35412528 Get It

SIGNIFICANCE A rigorously designed and calibrated symptom questionnaire for childhood intermittent exotropia would be useful for clinical care and for research. PURPOSE The aim of this study was to Rasch‐calibrate and evaluate the previously developed Child Intermittent Exotropia Symptom Questionnaire using data gathered as part of a randomized clinical trial. METHODS The questionnaire was administered to 386 children aged 3 to 10 years with intermittent exotropia who were enrolled in a randomized clinical trial comparing overminus with nonoverminus spectacles. Participants were followed at 6 and 12 months while on treatment and at 18 months off treatment. Factor analysis determined dimensionality, and Rasch analysis evaluated questionnaire performance. Logit values were converted to 0 (best) to 100 (worst). We evaluated differences in questionnaire scores between treatment groups and time points, and correlations with control scores. RESULTS The Child Intermittent Exotropia Symptom Questionnaire was unidimensional. Rasch analysis indicated that there was no notable local dependence and no significant differential item functioning for sex or age. There was suboptimal targeting (mean logit, −1.62), and person separation was somewhat poor (0.95). There were no significant differences in the Child Intermittent Exotropia Symptom score between overminus spectacles and nonoverminus spectacles at 6, 12, and 18 months. Combining data from both treatment groups, there was significant improvement from baseline at all follow‐up visits (e.g., mean change from baseline to 12 months, −6.6 points; 95% confidence interval, −8.6 to −4.6). Child Intermittent Exotropia Symptom scores were not correlated with distance or near control scores at 12 months. CONCLUSIONS The seven‐item Rasch‐scored Child Intermittent Exotropia Symptom Questionnaire is limited by suboptimal performance. Future study is needed to determine whether it may be useful for clinical practice and for research.
Prevalence and Outcomes of Bicuspid Aortic Valve in Patients With Aneurysmal Sub‐Arachnoid Hemorrhage: A Prospective Neurology Registry Report
Vallabhajosyula, Saarwaani , Thomas, Sarah , Maleszewski, Joseph J. , Boler, Amber, Thapa, Prabin , Enriquez‐Sarano, Maurice , Rabinstein, Alejandro A. , Michelena, Héctor I. , Yang, Li-Tan, Thomas, Sarah C, Maleszewski, Joseph J , Enriquez-Sarano, Maurice , Rabinstein, Alejandro A , Michelena, Hector I , Yang, Li‐Tan , Thomas, Sarah C.

Mayo Clinic

Journal of the American Heart Association | April 12, 2022 | Volume: 11 | Issue: 8 | Pages: No page available

10.1161/jaha.121.022339 | PMID 35411791 Get It

Background Intracranial aneurysms are reported in 6%–10% of patients with bicuspid aortic valve (BAV), and routine intracranial aneurysm surveillance has been advocated by some. We assessed the prevalence and features of the most important patient‐outcome: aneurysmal sub‐arachnoid hemorrhage (aSAH), as compared with controls without aSAH, and tricuspid aortic valve (TAV) with aSAH. Methods and Results Adult patients with accurate diagnosis of aSAH and at least one echocardiogram between 2000 and 2019 were identified from a consecutive prospectively maintained registry of aSAH admissions. Controls without a diagnosis of SAH were age‐ and sex‐matched. BAV prevalence was confirmed echocardiographically. Severity of aSAH was categorized using modified Fisher and World Federation of Neurological Scale. Neurologic outcome was assessed using modified Rankin score. A total 488 aSAH cases and 990 controls were identified and BAV status was confirmed. Prevalence of BAV in patients with aSAH was 1.2% (6/488) versus 3.5% (35/990) in controls, P =0.01. BAV+aSAH were noted to be younger than TAV+aSAH (56±11 versus 68±14; P =0.03) with smaller aneurysms (5±2 versus 7±4; P =0.31). The severity of aSAH was lesser in BAV+aSAH than TAV (modified Fisher grade>2 50% versus 74%; P =0.19, World Federation of Neurological Scale grade>3 17% versus 36%; P =0.43). BAV+aSAH had less severe neurologic disability (modified Rankin score 3%–6 33% versus 49% in TAV; P =0.44) and comparable in‐hospital mortality rates ( P =0.93). BAV had lower odds for aSAH on multivariate analysis (odds ratio 0.23[CI 0.08–0.65]; P =0.01). Conclusions Prevalence of BAV was 3 times lower in the aSAH registry than in controls without aSAH. BAV+aSAH had clinically smaller aneurysms, clinically smaller bleeds, and better neurologic outcome as compared with TAV+aSAH, which needs to be confirmed in larger studies. These findings argue against routine surveillance for intracranial aneurysms in patients with BAV without aortic coarctation.
Abstract P125: Change In Low-density Lipoprotein Cholesterol And Risk Of Subsequent Cardiovascular Events Among Patients With Myocardial Infarction
Manemann, Sheila M., Reading, Stephanie , Noshad, Sina , Weston, Susan A., Killian, Jill M. , Cohen, Sarah S. , Movva, Naimisha , Chamberlain, Alanna M.

Mayo Clinic

Circulation | April 7, 2022 | Volume: 145 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.145.suppl_1.p125 Get It

Background: Among patients who experience a myocardial infarction (MI), elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for experiencing a subsequent cardiovascular (CV) event; however, real-world evidence is lacking in regard to how changes in LDL-C levels after a MI hospitalization are related to subsequent CV events. Methods: Adults with a hospitalized MI and an available baseline LDL-C (closest LDL-C within 2 years prior to hospital discharge) between 2012 and 2018 within a 27-county region across MN and WI were included for study. For each LDL-C measurement during follow-up (starting with the first LDL-C >30 days after baseline and ≤1-year post-discharge), percent change from baseline LDL-C was calculated. Patients were followed for subsequent CV events (composite endpoint 1: MI, ischemic stroke [IS], coronary artery bypass grafting [CABG], percutaneous coronary intervention [PCI]; composite endpoint 2: MI, IS, CABG, PCI, CV death). Cox models were used to evaluate the association between time-dependent LDL-C percent change and CV events, stratified by baseline LDL-C (<70, 70-99, ≥100 mg/dL). Results: Among 3,034 MI patients identified, 740 (24%), 940 (31%) and 1354 (45%) had a baseline LDL-C <70, 70-99 and ≥100 mg/dL, respectively. After a mean follow-up of 3.4 years, 471 and 667 patients experienced the composite endpoint 1 and 2, respectively. After covariate adjustment, a trend towards a lower risk of CV events with decreasing LDL-C from baseline, compared to those with no change or an increase in LDL-C, was observed among those with a LDL-C <70 and > 100 mg/dl but not in those with a LDL-C 70-99 mg/dL (Table). Conclusions: In a population-based cohort of MI patients, there is evidence that patients with a decrease in LDL-C after MI may have a reduced risk of subsequent CV events. These results underscore the importance of lowering LDL-C after a MI and may help to identify subgroups at highest risk for additional CV events and those who may benefit from targeted LDL-C treatment recommendations.
Transcriptional landscape of human microglia implicates age, sex, and APOE‐related immunometabolic pathway perturbations
Patel, Tulsi , Carnwath, Troy , Wang, Xue , Allen, Mariet , Lincoln, Sarah, Lewis‐Tuffin, Laura J. , Quicksall, Zachary , Lin, Shu, Tutor‐New, Frederick Q, Ho, Charlotte C.G. , Min, Yuhao , Malphrus, Kimberly G., Nguyen, Thuy , Martin, Elizabeth, Al‐kharboosh, Rawan , Chaichana, Kaisorn L. , Wharen, Robert E. , Guerrero‐Cazares, Hugo , Quiñones‐Hinojosa, Alfredo , Ertekin‐Taner, Nilüfer , Carnwath, Troy P, Lincoln, Sarah J, Quicksall, Zachary S, Garcia, César A. , Alkharboosh, Rawan M, Chaichana, Kaisorn, Wharen, Robert, Ertekin-Taner, Nilüfer , Guerrero-Cazares, Hugo , Grewal, Sanjeet S.

Mayo Clinic

Aging Cell | April 7, 2022 | Volume: 21 | Issue: 5 | Pages: No page available

10.1111/acel.13606 | PMID 35388616 Get It

AbstractMicroglia have fundamental roles in health and disease; however, effects of age, sex, and genetic factors on human microglia have not been fully explored. We applied bulk and single‐cell approaches to comprehensively characterize human microglia transcriptomes and their associations with age, sex, and APOE. We identified a novel microglial signature, characterized its expression in bulk tissue and single‐cell microglia transcriptomes. We discovered microglial co‐expression network modules associated with age, sex, and APOE‐ε4 that are enriched for lipid and carbohydrate metabolism genes. Integrated analyses of modules with single‐cell transcriptomes revealed significant overlap between age‐associated module genes and both pro‐inflammatory and disease‐associated microglial clusters. These modules and clusters harbor known neurodegenerative disease genes including APOE, PLCG2, and BIN1. Meta‐analyses with published bulk and single‐cell microglial datasets further supported our findings. Thus, these data represent a well‐characterized human microglial transcriptome resource and highlight age, sex, and APOE‐related microglial immunometabolism perturbations with potential relevance in neurodegeneration.
P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
Popat, Rakesh , Badros, Ashraf , Kumar, Seema, Cohen, Alan R., Manier, Salomon , Voorhees, Peter M. , Rifkin, Robert M. , Martin, T., Jeng, Bennie H. , Lee, H, Berdeja, J. G., Jadhav, Vinay, Tosolini, A, Eliason, L, Palumbo, A, Trudel, S., Richardson, PG, Popat, Rakesh , Rodríguez‐Otero, Paula , Gay, Francesca , Chari, Ajai , Weisel, Katja C , Farooq, Asim V. , Chng, Wee Joo , Palumbo, Antonio , Dimopoulos, Meletios Α. , Lonial, Sagar , Terpos, Evangelos

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 18-18

10.1097/01.hs9.0000829624.40467.0d Get It

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Gay, Francesca Maria, Berdeja, J. G., Stefano, V De, Hooper, B, Haltner, A, Kumar, S, Martin, T, Mateos, MV, Moreau, P, Rosta, E, Samjoo, IA, Usmani, S. Z., Weisel, K, Cc, Jackson, Olyslager, Y, Schecter, JM, Vogel, M, Garrett, A, Lee, S, Nesheiwat, T, Pacaud, L, Zhou, C, Valluri, S, Lin, Y, Hari, Parameswaran , Hooper, Becky , Rosta, Emily, Weisel, Katja C , Olyslager, Yunsi, Schecter, JM, Garrett, Ashraf, Lee, S, Nesheiwat, T, Pacaud, Lida , Costa, Luciano J. , Lin, Yi

Mayo Clinic

HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 8-8

10.1097/01.hs9.0000829560.21894.ee Get It

Feasibility of Instituting a Clinical Otolaryngology Human Papillomavirus (HPV) Vaccination Program
Palacios, Victoria J. , Merlino, Dante J. , Anderson, Stephanie S., Yeakel, Sarah R., Wiedermann, Joshua P. , Moore, Eric J. , O’Byrne, Thomas J., Abel, Kathryn M. Van , Choby, Garret , Moore, Eric J , O'Byrne, Thomas J, Jacobson, Robert M. , Van Abel, Kathryn M , Yeakel, Sarah, Choby, Garret

Mayo Clinic

The Laryngoscope | April 2, 2022 | Volume: 133 | Issue: 1 | Pages: 116-123

10.1002/lary.30130 | PMID 35366006 Get It

ObjectivesTo measure baseline human papillomavirus (HPV) vaccination rates among tertiary and community‐based Otolaryngology – Head and Neck Surgery (Oto‐HNS) clinic patients and to determine risk factors for under‐vaccination.MethodsRetrospective chart review of patients aged 9 to 26 years presenting to an Oto‐HNS clinic from 2017 to 2019. Patients were considered complete for HPV vaccination if they received two doses of HPV vaccine with the first dose received before age 15 years or three doses of HPV vaccine otherwise.Results8,532 unique patients met the criteria. At the index visit, 3,110 (36.5%) had completed the HPV series, 5,422 (63.5%) were due for one or more doses, with 4,981 (58.4%) eligible for vaccination at the time of their appointment. Of those dues, most (3,148/5,422 or 58%) were past due by age (≥13 years old). Of the 3,148 patients past due, 745 (23.7%) were partially vaccinated and 2,403 (76.3%) were vaccine naïve. Male sex and younger age were both independently associated with incomplete vaccination (p < 0.0001).ConclusionThis study demonstrates that the implementation of on‐site HPV vaccination has the potential to increase the opportunities for vaccination among vaccine‐eligible patients, especially among young males. Otolaryngologists have the potential to provide meaningful preventive services in the fight against HPV‐mediated disease.Level of Evidence3 Laryngoscope, 133:116–123, 2023
Facilitators and Barriers to the Implementation of New Critical Care Practices during COVID-19: A Multicenter Qualitative Study using the Consolidated Framework for Implementation Research (CFIR)
Silver, Santana , Jones, Kayla Christine , Redmond, Sarah , George, Emily , Zornes, Sarah, Leppin, Aaron L. , Harmon, Lori, Kumar, Vishakha K. , Kordik, Christina, Barwise, Amelia , Dong, Yue , Walkey, Allan J. , Drainoni, Mari‐Lynn

Mayo Clinic

No container title available | April 1, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1510788/v1 Get It

Abstract Background The COVID-19 pandemic produced unprecedented demands and rapidly changing evidence and practices within critical care settings. The purpose of this study was to identify factors and strategies that hindered and facilitated effective implementation of new critical care practices and policies in response to the pandemic. Methods We used a cross-sectional, qualitative study design to conduct semi-structured in-depth interviews with critical care leaders across the United States. The interviews were audio-taped and professionally transcribed verbatim. Guided by the Consolidated Framework for Implementation Research (CFIR), three qualitative researchers used rapid analysis methods to develop relevant codes and identify salient themes. Results Among the 17 hospitals that agreed to participate in this study, 31 clinical leaders were interviewed. The CFIR-driven rapid analysis of the interview transcripts generated 12 major themes, which included six implementation facilitators (i.e., factors that promoted the implementation of new critical care practices) and six implementation barriers (i.e., factors that hindered the implementation of new critical care practices). These themes spanned the five CFIR domains (Intervention Characteristics, Outer Setting, Inner Setting, Characteristics of Individuals, and Process) and 11 distinct CFIR constructs. Salient facilitators to implementation efforts included staff resilience, commitment, and innovation, which were supported through collaborative feedback and decision-making mechanisms between leadership and frontline staff. Major identified barriers included lack of access to reliable and transferable information, available resources, uncollaborative leadership and communication styles. Conclusions Through applying the CFIR to organize and synthesize our qualitative data, this study revealed important insights into implementation determinants that influenced the uptake of new critical care practices during COVID-19. As the pandemic continues to burden critical care units, clinical leaders should consider emulating the effective change management strategies identified. The cultivation of streamlined, engaging, and collaborative leadership and communication mechanisms not only supported implementation of new care practices across sites, but it also helped reduce salient implementation barriers, particularly resource and staffing shortages. Future critical care implementation studies should seek to capitalize on identified facilitators and reduce barriers.